⚠ HIGH ALERT

maraviroc (Rx)

(mah-rav′er-rock)

Selzentry

Func. class.: Antiretroviral

Chem. class.: Fusion inhibitor, CCR5-receptor antagonist

ACTION: Interferes with entry into HIV-1 by inhibiting the fusion of the virus and the cell membrane

USES: CCR5-tropic HIV in combination with other antiretroviral agents for treating experienced patients

CONTRAINDICATIONS: Hypersensitivity, dialysis, renal impairment

Precautions: Pregnancy, Asian patients, breastfeeding, renal/hepatic/cardiac disease, electrolyte imbalance, dehydration, immune reconstitution syndrome, infection, MI, orthostatic hypotension, children, geriatric patients, Graves' disease, Guillain-Barré syndrome, polymyositis, fever, serious rash

Black Box Warning: Hepatitis

DOSAGE AND ROUTES

Those not taking any CYP3A inducers/inhibitors

• **Adult/adolescent ≥16 yr: PO** 300 mg bid

Those taking CYP3A4 inhibitors with/without a CYP3A inducer

• **Adult/adolescent ≥16 yr: PO** 150 mg bid

Those taking CYP3A4 inducers without a strong CYP3A inhibitor

• **Adult/adolescent ≥16 yr: PO** 600 mg bid

Renal dose

• **Adult: PO** CCr ≥30 mL/min, no dose adjustment; CCr <30 mL/min, use is contraindicated

Available forms: Tabs 150, 300 mg

Administer:

• May give without regard to meals, with 8 oz water; swallow whole; do not crush, chew, break

• Store at room temperature

SIDE EFFECTS

CV: MI, cardiac ischemia, orthostatic hypotension

CNS: Dizziness, depression, viral meningitis, disturbances in consciousness, peripheral neuropathy, paresthesia, dysesthesia, fever

EENT: Gingival hyperplasia, visual changes

GI: Diarrhea, constipation, dyspepsia, pseudomembranous colitis, hepatotoxicity

INTEG: Rash, urticaria, pruritus, folliculitis

MS: Joint pain, leg pain, muscle cramps

RESP: Cough, upper respiratory tract infection, sinusitis, bronchitis, pneumonia, bronchospasm, obstruction, dyspnea

SYST: Herpes virus, lipodystrophy, malignancy

PHARMACOKINETICS

Metabolized by P450 system; CYP3A metabolism; excreted 20% urine, 76% feces; protein binding 76%; terminal half-life 14-18 hr

INTERACTIONS

Increase: maraviroc levels—CYP3A inhibitors (amiodarone, aprepitant, chloramphenicol, clarithromycin, conivaptan, cycloSPORINE, dalfopristin, danazol, diltiaZEM, erythromycin, estradiol, fluconazole, fluvoxaMINE, imatinib, isoniazid, itraconazole, ketoconazole, miconazole, nefazodone, niCARdipine, propoxyphene, RU-486, tamoxifen, telithromycin, troleandomycin, verapamil, voriconazole, zafirlukast); reduce dose

Decrease: maraviroc levels—CYP3A4 inducers (efavirenz, aminoglutethimide, barbiturates, bexarotene, bosentan, carBAMazepine, dexamethasone, griseofulvin, modafinil, nafcillin, OXcarbazepine, phenytoin, fosphenytoin, rifabutin, rifAMPin, rifapentine, topiramate, tipranavir); increase dose

Drug/Herb

• Decreased maraviroc effect: St. John's wort